498 related articles for article (PubMed ID: 21272091)
1. Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia.
Yokoyama T; Hara R; Fukumoto K; Fujii T; Jo Y; Miyaji Y; Nagai A; Sone A
Int J Urol; 2011 Mar; 18(3):225-30. PubMed ID: 21272091
[TBL] [Abstract][Full Text] [Related]
2. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E;
Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
4. Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
Yu HJ; Lin AT; Yang SS; Tsui KH; Wu HC; Cheng CL; Cheng HL; Wu TT; Chiang PH
BJU Int; 2011 Dec; 108(11):1843-8. PubMed ID: 21592295
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of combination therapy with mirodenafil and α1-blocker for benign prostatic hyperplasia-induced lower urinary tract symptoms accompanied by erectile dysfunction: a multicenter, open-label, prospective study.
Lee JY; Cho SY; Oh CY; Ha US; Lee SH; Park SY; Moon HS; Lee SW
Int J Impot Res; 2011; 23(6):249-56. PubMed ID: 21814227
[TBL] [Abstract][Full Text] [Related]
6. Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study.
Masumori N; Tsukamoto T; Iwasawa A; Furuya R; Sonoda T; Mori M;
Urol Int; 2009; 83(1):49-54. PubMed ID: 19641359
[TBL] [Abstract][Full Text] [Related]
7. Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial.
Yamaguchi K; Aoki Y; Yoshikawa T; Hachiya T; Saito T; Takahashi S
Int J Urol; 2013 Dec; 20(12):1234-8. PubMed ID: 23731168
[TBL] [Abstract][Full Text] [Related]
8. [Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe].
Chapple ChR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernandez Fernandez E
Urologiia; 2012; (5):38-42, 44-5. PubMed ID: 23342615
[TBL] [Abstract][Full Text] [Related]
9. Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin-controlled, 12-week double-blind study.
Giuliano F; Oelke M; Jungwirth A; Hatzimouratidis K; Watts S; Cox D; Viktrup L
J Sex Med; 2013 Mar; 10(3):857-65. PubMed ID: 23346990
[TBL] [Abstract][Full Text] [Related]
10. Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia.
Homma Y; Kawabe K; Takeda M; Yoshida M
Urology; 2010 Dec; 76(6):1446-50. PubMed ID: 20472263
[TBL] [Abstract][Full Text] [Related]
11. Short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia.
Miyakita H; Yokoyama E; Onodera Y; Utsunomiya T; Tokunaga M; Tojo T; Fujii N; Yanada S
Int J Urol; 2010 Oct; 17(10):869-75. PubMed ID: 20735791
[TBL] [Abstract][Full Text] [Related]
12. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men.
Kawabe K; Yoshida M; Homma Y;
BJU Int; 2006 Nov; 98(5):1019-24. PubMed ID: 16945121
[TBL] [Abstract][Full Text] [Related]
13. α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy.
Yamaguchi S; Osanai H; Numata A; Watanabe M; Kakizaki H
Int J Urol; 2013 May; 20(5):513-9. PubMed ID: 23078534
[TBL] [Abstract][Full Text] [Related]
14. Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial.
Tsumura H; Satoh T; Ishiyama H; Tabata K; Kotani S; Minamida S; Kimura M; Fujita T; Matsumoto K; Kitano M; Hayakawa K; Baba S
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e385-92. PubMed ID: 21664068
[TBL] [Abstract][Full Text] [Related]
15. A prospective, randomized, controlled, multicenter study of naftopidil for treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: 75 mg once daily in the evening compared to 25 mg thrice daily.
Tsuritani S; Nozaki T; Okumura A; Kimura H; Kazama T
Urol Int; 2010; 85(1):80-7. PubMed ID: 20516676
[TBL] [Abstract][Full Text] [Related]
16. [Optimum initial dose of silodosin for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia].
Wada N; Numata A; Yamaguchi S; Osanai H; Mori T; Hou K; Fujisawa M; Kaneko S; Kakizaki H
Hinyokika Kiyo; 2011 Jun; 57(6):297-302. PubMed ID: 21795831
[TBL] [Abstract][Full Text] [Related]
17. A randomized crossover study comparing patient preference for tamsulosin and silodosin in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.
Watanabe T; Ozono S; Kageyama S
J Int Med Res; 2011; 39(1):129-42. PubMed ID: 21672315
[TBL] [Abstract][Full Text] [Related]
18. Effects of silodosin on sexual function - realistic picture from the everyday clinical practice.
Capogrosso P; Serino A; Ventimiglia E; Boeri L; Dehò F; Damiano R; Briganti A; Montorsi F; Salonia A
Andrology; 2015 Nov; 3(6):1076-81. PubMed ID: 26446512
[TBL] [Abstract][Full Text] [Related]
19. Combined tadalafil and α-blocker therapy for benign prostatic hyperplasia in patients with erectile dysfunction: a multicenter, prospective study.
Lee JY; Park SY; Jeong TY; Moon HS; Kim YT; Yoo TK; Choi HY; Park HY; Lee SW
J Androl; 2012; 33(3):397-403. PubMed ID: 21868753
[TBL] [Abstract][Full Text] [Related]
20. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Singh DV; Mete UK; Mandal AK; Singh SK
J Sex Med; 2014 Jan; 11(1):187-96. PubMed ID: 24165272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
